Skip to main content
. 2021 Sep 20;5:96. doi: 10.1186/s41687-021-00372-4

Table 8.

Unadjusted mean scores (± SD) of EORTC QLQ-NMIBC24 subscales for 541 NMIBC patients participating in UroLife at three time points after diagnosis and mean differences at 3 months (T3mo) and 15 months (T15mo) compared to 6 weeks (T6wk) after diagnosis (responsiveness)

Patient score, mean (SD) Effect sizea
T6wk (N = 541) T3mo (N = 471) T15mo (N = 423) T3mo vs. T6wk T15mo vs. T6wk
Urinary symptoms (–)e 28.4 (21.0) 22.3 (19.3) 17.8 (16.4) − 0.27d − 0.53d
Malaise (–)e 3.7 (12.1) 3.4 (10.5) 2.5 (9.5) − 0.02 − 0.08
Future worries (–)e 33.6 (24.1) 29.5 (22.6) 24.7 (21.4) − 0.17d − 0.38d
Bloating and flatulence (–)e 17.4 (21.2) 17.1 (20.4) 14.4 (18.0) 0.00 − 0.14c
Sexual functioning (+)e 21.9 (22.6) 24.4 (22.2) 27.1 (23.2) 0.09d 0.23d
Male sexual problems (–)e 28.1 (32.6) 27.5 (31.2) 33.3 (33.0) − 0.01 0.12b
Intravesical treatment issues (–)e 10.0 (18.8) 9.5 (18.7) 6.2 (15.7) 0.02 − 0.23d
Sexual intimacy (–)e 13.8 (22.4) 10.4 (20.0) 10.1 (19.2) − 0.20c − 0.29c
Risk of contaminating partner (–)e 19.3 (27.0) 14.3 (22.7) 10.0 (21.5) − 0.20b − 0.46d
Sexual enjoyment (+)e 45.0 (29.7) 42.9 (26.5) 41.9 (29.1) − 0.12 − 0.20b
Female sexual problems (–)e 33.3 (25.8) 18.8 (36.5) 12.7 (24.7) − 0.34 − 1.16b

aEffect size was calculated using Cohen’s d statistic (mean difference divided by pooled standard deviation) and 0.2 is considered small, 0.5 moderate, and 0.8 large

bp ≤ 0.05

cp ≤ 0.01

dp ≤ 0.001

eThe signs (–) and (+) indicate whether higher scores on this scale are worse or better, respectively